Randomized control study of eradication therapy for Helicobacter pylori

Randomized control study of eradication therapy for Helicobacter pylori - Randomized control study of eradication therapy for Helicobacter pylori

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004837

Enrollment

120

Registered

2011-01-07

Start date

2007-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrophic gastritis, Gastric ulcer, Duodenal ulcer

Interventions

7-day quadruple therapy (lansoprazole, amoxicillin, clarithromycin, metronidazole ) 7-day triple therapy(lansoprazole, amoxicillin, clarithromycin, metronidazole)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: H. pylori infected patients diagnosed with peptic ulcer or atrophic gastritis by endoscopic examinations.

Exclusion criteria

Exclusion criteria: (1) age less than 18 years, (2)allergy to antibiotics, (3) active peptic ulcer undergoing PPI treatment, (4) present malignancy or history of malignancy, (5) previous subtotal or total gastrectomy, (6) pregnancy or nursing, and (7) previous failed H. pylori eradication therapy.

Design outcomes

Primary

Measure	Time frame
The efficacy of eradication treatment which is evaluated by 13C-urea breath test three month after treatment.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026